Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. (Nasdaq: VCYT) is a global cancer diagnostics and genomic testing company whose news flow centers on clinical evidence, test performance, and financial results. The company describes its mission as transforming cancer care by empowering clinicians with high-value insights at key decision points in diagnosis and treatment. Its Veracyte Diagnostics Platform underpins tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, along with research tools like Afirma GRID and Decipher GRID.
On this page, readers can follow Veracyte news related to quarterly and annual financial results, including revenue and testing volume updates the company announces in earnings press releases and accompanying conference calls. Veracyte’s communications also highlight non-GAAP measures such as adjusted EBITDA and adjusted EBITDA margin, along with explanations of how these metrics are used internally and how they differ from GAAP figures.
Another major category of news involves clinical and scientific developments. Veracyte regularly reports on studies and abstracts that use its Afirma GRID and Decipher GRID platforms to develop and evaluate molecular signatures in thyroid and prostate cancer. Examples include publications on Afirma GRID-derived signatures to differentiate thyroid cancer risk groups and prospective validation data for biomarkers such as the PAM50 molecular signature in recurrent prostate cancer.
Investors and clinicians can also find announcements about Veracyte’s participation in healthcare and investor conferences, where management presents updates on the company’s diagnostics portfolio, research programs, and financial outlook. For ongoing insight into how Veracyte’s genomic tests and research tools are being used in practice and studied in trials, this news feed aggregates the company’s press releases and related updates in one place.
Veracyte (VCYT) announced new data supporting its Decipher Bladder Genomic Subtyping Classifier's effectiveness in improving bladder cancer staging. The study, published in European Urology Open Science, analyzed 226 patients from eight medical centers who underwent radical cystectomy without neoadjuvant chemotherapy.
Key findings showed that 33% of patients experienced pathological upstaging to non-organ-confined disease (19% for NMIBC and 53% for T2 disease). The study revealed that NMIBC patients with non-luminal tumors were more likely to be upstaged to MIBC compared to those with luminal tumors (51% vs. 32%). Additionally, patients with luminal-subtype bladder cancer demonstrated better overall survival based on a 33-month median follow-up.
This research adds to Veracyte's growing clinical evidence supporting its molecular tests in urology, where its Decipher Prostate Genomic Classifier is already the market leader.
Veracyte (VCYT), a leading cancer diagnostics company, has announced it will release its Q4 and full-year 2024 financial results after market close on Monday, February 24, 2025. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update. The event will be accessible through a live webcast from the company's website, with dial-in registration available for the conference call. A webcast replay will be made available on the company's investor relations website following the broadcast.
Veracyte's Decipher Prostate Genomic Classifier has achieved a significant milestone as the only gene expression test included in the 2025 NCCN Clinical Practice Guidelines for prostate cancer. The test, which uses a 22-gene signature to assess the likelihood of prostate tumor metastasis, helps clinicians make informed treatment decisions.
The test's inclusion in the guidelines is backed by extensive validation through numerous peer-reviewed studies and analyses from multiple Phase 3 clinical trials. As the most widely used molecular test in prostate cancer, this recognition in the NCCN guidelines is expected to increase its accessibility to more patients.
Veracyte reported its third quarter 2024 financial results, showing a 29% increase in total revenue to $115.9 million and a 34% rise in testing revenue to $109.5 million. The company achieved a net income of $15.2 million, a 151% improvement year-over-year, with adjusted EBITDA growing by 117% to $27.3 million. Testing volume increased by 24% to 36,792 tests, driven by strong performance in Decipher and Afirma tests. Decipher revenue grew by 48%, while Afirma revenue increased by 19%. Product revenue and biopharmaceutical revenue saw declines of 21% and 23%, respectively. Veracyte raised its full-year 2024 revenue guidance to $442-$445 million, representing 22%-23% growth. The company expects year-end cash and equivalents to be between $280-$285 million.
Veracyte (VCYT) has announced its participation in four major investor conferences in November. The cancer diagnostics company will conduct fireside chats at the UBS Healthcare Conference (November 12th, 2:45 PM ET), Guggenheim Inaugural Healthcare Innovation Conference (November 13th, 3:00 PM ET), Wolfe Research Healthcare Conference (November 19th, 1:40 PM ET), and Stephens Annual Investor Conference (November 20th, 4:00 PM ET). Live audio webcasts will be available on Veracyte's investor website, with replays accessible for 90 days after each presentation.
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced the release date for its third quarter 2024 financial results. The company will disclose these results after the market closes on Wednesday, November 6, 2024.
Following the release, Veracyte's management team will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day. This event will provide a general business update and discuss the financial results. Investors and interested parties can access the live webcast through the company's website or via the provided link: https://edge.media-server.com/mmc/p/kzh3s376.
For those unable to attend the live event, a webcast replay will be made available on Veracyte's investor relations website. Conference call dial-in information can be obtained by registering at the provided link.
Veracyte, Inc. (Nasdaq: VCYT) announced new data from the VANDAAM trial showing that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer in African American men with early-stage disease. The findings were presented at ASTRO 2024 in Washington, D.C.
Key points:
- African American men are 70% more likely to be diagnosed with prostate cancer and twice as likely to die from it compared to white men.
- The study included 226 men (113 African American and 113 non-African American) with low- or intermediate-risk prostate cancer.
- Patients with high Decipher test scores were eight times more likely to have biochemical recurrence within 2 years.
- Results showed no significant difference between African American and non-African American men.
This study is the first prospective clinical trial examining genomic risk-stratification in African American men, potentially helping to narrow the prostate cancer disparity gap.
Veracyte (NASDAQ: VCYT) presented new data at ESMO 2024 showing that its Decipher Prostate Genomic Classifier predicts chemotherapy benefit in patients with metastatic prostate cancer. The findings, from an ancillary study of the phase 3 STAMPEDE trial, support Veracyte's plan to expand the Decipher Prostate test to metastatic disease.
Key findings include:
- Higher Decipher scores were associated with increased risk of death
- Patients with higher scores showed a 36% reduction in death risk with docetaxel addition
- The test predicted benefit regardless of cancer volume
Veracyte plans to offer the test for metastatic prostate cancer in early 2025, pending Medicare reimbursement. This expansion demonstrates the power of Veracyte's Diagnostics Platform in delivering high-performing cancer tests and generating evidence for reimbursement and adoption.
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. Mr. Shafer, with over 40 years of experience in healthcare technologies, will serve on the Compensation Committee. Dr. Miller, a scientist and entrepreneur focusing on AI, chemistry, and biology, will join the Regulatory and Compliance Committee.
Mr. Shafer's background includes roles as chairman and CEO of Cerner and CEO of Philips North America. Dr. Miller is the co-founder and CEO of Iambic Therapeutics and a former tenured professor at Caltech. Both new board members expressed enthusiasm for Veracyte's mission and potential impact on cancer diagnostics and patient care.
Veracyte (Nasdaq: VCYT) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. CEO Marc Stapley and CFO Rebecca Chambers will engage in a fireside chat on Thursday, September 5, at 2:35 p.m. Eastern Time.
Investors and interested parties can access a live audio webcast of the presentation through Veracyte's website at http://investor.veracyte.com/events-presentations. For those unable to attend the live event, a replay of the webcast will be available for 90 days following the presentation.
This participation highlights Veracyte's commitment to engaging with the investment community and sharing insights about the company's progress and future prospects in the healthcare sector.
FAQ
What is the current stock price of Veracyte (VCYT)?
What is the market cap of Veracyte (VCYT)?
